RESUMO
OBJECTIVES: To familiarize medical providers with the Food and Drug Administration approval process for antiobesity devices and to provide a brief overview of current and promising endoscopy-based bariatric devices. METHODS: Literature review of published scholarly articles. RESULTS: There has been a rapid development of novel endoscopic bariatric therapies in recent years, resulting in the approval of multiple devices. Several promising endoscopic strategies are currently under investigation and review. The Food and Drug Administration has laid down an objective-tiered model to review antiobesity device applications. DISCUSSION: Endoscopic bariatric devices provide a new and promising paradigm in obesity management both as first-line therapy and as adjunctive treatment to medical and surgical strategies. Physicians who plan to offer endoscopic bariatric therapy in their practice need appropriate understanding of the regulatory processes involved in the development and approval of such devices.
Assuntos
Cirurgia Bariátrica/instrumentação , Aprovação de Equipamentos , Endoscopia Gastrointestinal/instrumentação , Manejo da Obesidade/tendências , Obesidade Mórbida/cirurgia , Terapia por Estimulação Elétrica/instrumentação , Balão Gástrico , Humanos , Estados Unidos , United States Food and Drug AdministrationAssuntos
Traumatismos Abdominais/cirurgia , Fístula Biliar , Colangiopancreatografia Retrógrada Endoscópica/métodos , Fístula Cutânea , Procedimentos Cirúrgicos do Sistema Digestório/efeitos adversos , Complicações Pós-Operatórias , Implantação de Prótese , Stents/efeitos adversos , Adulto , Ductos Biliares/diagnóstico por imagem , Ductos Biliares/cirurgia , Fístula Biliar/diagnóstico , Fístula Biliar/etiologia , Fístula Biliar/fisiopatologia , Fístula Biliar/cirurgia , Fístula Cutânea/diagnóstico , Fístula Cutânea/etiologia , Fístula Cutânea/fisiopatologia , Fístula Cutânea/cirurgia , Procedimentos Cirúrgicos do Sistema Digestório/instrumentação , Procedimentos Cirúrgicos do Sistema Digestório/métodos , Desenho de Equipamento , Feminino , Humanos , Traumatismo Múltiplo/cirurgia , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/fisiopatologia , Complicações Pós-Operatórias/cirurgia , Implantação de Prótese/instrumentação , Implantação de Prótese/métodos , Resultado do Tratamento , Ferimentos por Arma de Fogo/cirurgiaRESUMO
Obesity and its associated cardio-metabolic comorbidities have emerged as a global pandemic. The efficacy of various hypo-caloric diets and prescription drugs has been poor with respect to sustained weight loss. Recent advancements in endoscopic technology and techniques have opened a new field of minimally invasive endoscopic treatment options for combatting obesity both as a first line and adjunctive therapy. Presently, two endoscopic space-occupying devices in the form of intragastric balloons have received FDA approval for 6-month implantation in patients within a BMI range of 30-40 kg/m(2). Furthermore, full-thickness suturing has led to the development of primary endoscopic sleeve gastroplasty and Roux-en-Y gastric bypass revision as viable endoscopic alternatives to surgical approaches. These techniques have the potential to reduce adverse events, cost, and recovery times. Looking forward, a variety of promising and novel medical devices and endoscopic platforms that target obesity and diabetes are in various phases of development and investigation. The present review aims to discuss the current and forthcoming endoscopic bariatric therapies with emphasis on relevant procedural technique and review of available evidence.
Assuntos
Cirurgia Bariátrica/métodos , Endoscopia Gastrointestinal/métodos , Obesidade/cirurgia , Cirurgia Bariátrica/instrumentação , Cirurgia Bariátrica/tendências , Endoscopia Gastrointestinal/instrumentação , Balão Gástrico , Derivação Gástrica/métodos , Gastroplastia/métodos , Humanos , Cuidados Pós-Operatórios/métodosRESUMO
Pituitary adenylate cyclase-activating peptide (PACAP) is expressed within the gastroenteric system, where it has profound physiological effects. PACAP was shown to regulate food intake and thermogenesis centrally; however, PACAP peripheral regulation of appetite and feeding behavior is unknown. Therefore, we studied PACAP's effect on appetite and food intake control by analyzing feeding behavior and metabolic hormones in PAC1-deficient (PAC1-/-) and age-matched wild-type (WT) mice intraperitoneally injected with PACAP1-38 or PACAP1-27 before the dark phase of feeding. Food intake and feeding behavior were analyzed using the BioDAQ system. Active ghrelin, glucagon-like peptide-1 (GLP-1), leptin, peptide YY, pancreatic polypeptide, and insulin were measured following PACAP1-38 administration in fasted WT mice. PACAP1-38/PACAP1-27 injected into WT mice significantly decreased in a dose-dependent manner cumulative food intake and reduced bout and meal feeding parameters. Conversely, PACAP1-38 injected into PAC1-/- mice failed to significantly change food intake. Importantly, PACAP1-38 reduced plasma levels of active ghrelin compared with vehicle in WT mice. In PAC1-/- mice, fasting levels of active ghrelin, GLP-1, insulin, and leptin and postprandial levels of active ghrelin and insulin were significantly altered compared with levels in WT mice. Therefore, PAC1 is a novel regulator of appetite/satiety. PACAP1-38/PACAP1-27 significantly reduced appetite and food intake through PAC1. In PAC1-/- mice, the regulation of anorexigenic/orexigenic hormones was abolished, whereas active ghrelin remained elevated even postprandially. PACAP significantly reduced active ghrelin in fasting conditions. These results establish a role for PACAP via PAC1 in the peripheral regulation of appetite/satiety and suggest future studies to explore a therapeutic use of PACAP or PAC1 agonists for obesity treatment.